RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients

BACKGROUND: Since circulating tumor DNA (ctDNA) offers clear advantages as a minimally invasive method for tumor monitoring compared with tumor tissue, we aimed to evaluate genotyping ctDNA using a next-generation sequencing- (NGS-) based panel to identify the prognostic value of mutation status in...

Descripción completa

Detalles Bibliográficos
Autores principales: Yao, Jiannan, Zang, Wanchun, Ge, Yang, Weygant, Nathaniel, Yu, Pan, Li, Lei, Rao, Guanhua, Jiang, Zhi, Yan, Rui, He, Linjia, Yu, Yang, Jin, Mulan, Cheng, Gang, An, Guangyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5863340/
https://www.ncbi.nlm.nih.gov/pubmed/29707525
http://dx.doi.org/10.1155/2018/4248971

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5863340/
https://www.ncbi.nlm.nih.gov/pubmed/29707525
http://dx.doi.org/10.1155/2018/4248971

Ejemplares similares